| Literature DB >> 27220316 |
Khaoula Ben-Farhat1,2, Imen Ben-Mustapha3,4,5, Meriem Ben-Ali1,2, Karen Rouault6, Saber Hamami7, Najla Mekki1,2,8, Amel Ben-Chehida9, Beya Larguèche1, Zohra Fitouri10, Selim Abdelmoula9, Monia Khemiri11, Mohamed-Neji Guediche7, Samir Boukthir12, Sihem Barsaoui11, Jalel Chemli13, Mohamed-Ridha Barbouche1,2,8.
Abstract
Chronic granulomatous disease (CGD) is the prototypic functional neutrophil disorder caused by genetic defects in one of the five genes encoding the superoxide-generating nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase subunits of phagocytes. Mutations causing the most prevalent form of CGD in western populations are located in the X-linked-CYBB gene. The four remaining autosomal recessive (AR) forms collectively account for one-third of CGD cases. We investigated the clinical and molecular features of eleven patients with CGD from 6 consanguineous families, originating from contiguous regions in the west of Tunisia. The patients' clinical phenotype is characterized by a high incidence of mycobacterial infections. Five out of the eleven patients died despite treatment arguing in favor of a severe clinical form of CGD. These findings correlated with the absence of functional p67phox protein as well as the absence of residual reactive oxygen intermediates (ROI) production. Genetic analysis showed the presence, in all patients, of a unique mutation (c.257 + 2T > C) in NCF2 gene predicted to affect RNA splicing. Segregating analysis using nine polymorphic markers overlapping the NCF2 gene revealed a common haplotype spanning 4.1 Mb. The founder event responsible for this mutation was estimated to have arisen approximately 175 years ago. These findings will facilitate the implementation of preventive approaches through genetic counseling in affected consanguineous families.Entities:
Keywords: Chronic granulomatous disease; NCF2 gene; Tunisia; consanguinity; founder effect
Mesh:
Substances:
Year: 2016 PMID: 27220316 DOI: 10.1007/s10875-016-0299-9
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.317